| P2093 | author name string | V Gupta | |
| | S Giralt | |
| | R Hoffman | |
| | D Rondelli | |
| | F Pane | |
| | G Finazzi | |
| | J Mascarenhas | |
| | T I Mughal | |
| | R Hasserjian | |
| | J Prchal | |
| | V Fauble | |
| | R Tamari | |
| | O Odenike | |
| P2860 | cites work | Interferon alfa in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms | Q84114126 |
| | MPN blast phase: clinical challenge and assessing response | Q85015128 |
| | Long-term outcome of treatment with ruxolitinib in myelofibrosis | Q85087797 |
| | From nuclear to a global family: more donors for MDS | Q85751874 |
| | Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation | Q87247099 |
| | Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 |
| | Ruxolitinib in combination with DNA methyltransferase inhibitors: clinical responses in patients with symptomatic myelofibrosis with cytopenias and elevated blast(s) counts | Q87753909 |
| | Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis | Q88113626 |
| | The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes | Q22299206 |
| | Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2 | Q24568313 |
| | Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation | Q27684364 |
| | Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia | Q29547900 |
| | CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons | Q29998841 |
| | Standardization of bone marrow features--does it work in hematopathology for histological discrimination of different disease patterns? | Q33212356 |
| | European consensus on grading bone marrow fibrosis and assessment of cellularity | Q33221061 |
| | Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation | Q33366694 |
| | A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms | Q33390255 |
| | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment | Q79802927 |
| | Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia | Q79817900 |
| | Quantitative evaluation of bone marrow angiogenesis in idiopathic myelofibrosis | Q80064780 |
| | Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens | Q80262366 |
| | Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia | Q81321013 |
| | The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries | Q84065231 |
| | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). | Q33393151 |
| | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status | Q33393245 |
| | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis | Q33399977 |
| | A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 |
| | Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis | Q33400570 |
| | Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis | Q33400683 |
| | A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). | Q33405372 |
| | Enrichment of FLI1 and RUNX1 mutations in families with excessive bleeding and platelet dense granule secretion defects | Q33410783 |
| | Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party o | Q33558748 |
| | Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms | Q33880512 |
| | Outcome of transplantation for myelofibrosis | Q34015474 |
| | Somatic mutations of calreticulin in myeloproliferative neoplasms | Q34039270 |
| | MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis | Q34047897 |
| | Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies | Q34158356 |
| | An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor | Q34343220 |
| | TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients | Q34398397 |
| | Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. | Q34541582 |
| | Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies | Q35132241 |
| | A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis. | Q35206418 |
| | Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents | Q35603419 |
| | Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis | Q35735663 |
| | The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation | Q35849342 |
| | Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. | Q35984641 |
| | Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: a forgotten pearl | Q36509782 |
| | Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs | Q36915139 |
| | Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres | Q36957972 |
| | Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. | Q37163590 |
| | (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible | Q37332185 |
| | Novel insights into the biology and treatment of chronic myeloproliferative neoplasms | Q37361527 |
| | Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. | Q37457111 |
| | Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib | Q37652919 |
| | Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? | Q37968531 |
| | Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase | Q38009467 |
| | Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors | Q38018908 |
| | JAK2 inhibitors in the treatment of myeloproliferative neoplasms. | Q38044736 |
| | An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms | Q38179853 |
| | Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) | Q38242725 |
| | Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia | Q39478326 |
| | Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia | Q39695762 |
| | Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. | Q39977224 |
| | The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis | Q40265956 |
| | Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms | Q42551545 |
| | Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. | Q42583748 |
| | Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia | Q42720284 |
| | Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). | Q42955257 |
| | Therapeutic options for patients with myelofibrosis in blast phase | Q42971653 |
| | Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation | Q43265365 |
| | The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo | Q43451422 |
| | Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia | Q43904556 |
| | Mutations and prognosis in primary myelofibrosis | Q44429606 |
| | FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia | Q44571772 |
| | Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups. | Q44678769 |
| | Nongenomic effects of 17beta-estradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor beta and Src kinase. | Q44938060 |
| | From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms | Q45778614 |
| | Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis | Q45881388 |
| | U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. | Q45961967 |
| | Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis | Q46919614 |
| | Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type | Q47174502 |
| | Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis | Q47589093 |
| | The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients | Q48680927 |
| | Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. | Q50453985 |
| | Allogeneic hematopoietic cell transplantation for chronic myelofibrosis in Australia and New Zealand: older recipients receiving myeloablative conditioning at increased mortality risk. | Q50534892 |
| | Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. | Q50890627 |
| | Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. | Q51023659 |
| | Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis. | Q53094253 |
| | Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. | Q53099028 |
| | Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. | Q53136705 |
| | Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. | Q54349909 |
| | JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis. | Q54374933 |
| | Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. | Q54646707 |
| | Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis. | Q54730665 |
| | Allogeneic hematopoietic cell transplantation for myelofibrosis using fludarabine-, intravenous busulfan- and low-dose TBI-based conditioning | Q60710884 |
| | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). | Q61050093 |
| | CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis | Q61758700 |
| | Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) | Q64008518 |
| | Splenectomy and hemopoietic stem cell transplantation for myelofibrosis | Q73709920 |
| | Myelofibrosis with myeloid metaplasia | Q73712758 |
| | Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Resea | Q77363568 |
| | Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading | Q79426706 |
| | Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation | Q79751355 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | myelofibrosis | Q1752571 |
| P304 | page(s) | 628-636 | |
| P577 | publication date | 2015-02-09 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | Allo-SCT for myelofibrosis: reversing the chronic phase in the JAK inhibitor era? | |
| P478 | volume | 50 | |